(FATE) Fate Therapeutics - Performance -71% in 12m
FATE performance: live returns, drawdowns, peer ranking & SPY comparison from 1w to 5y, all in one clean chart-driven dashboard.
Performance Rating
-95.55%
#199 in Peer-Group
Rel. Strength
4.52%
#7339 in Stock-Universe
Total Return 12m
-70.95%
#161 in Peer-Group
Total Return 5y
-96.72%
#155 in Peer-Group
| P/E | Value |
|---|---|
| P/E Trailing | - |
| P/E Forward | - |
| High / Low | USD |
|---|---|
| 52 Week High | 5.57 USD |
| 52 Week Low | 0.68 USD |
| Sentiment | Value |
|---|---|
| VRO Trend Strength +-100 | 56.66 |
| Buy/Sell Signal +-5 | -1.60 |
| Support / Resistance | Levels |
|---|---|
| Support | |
| Resistance |
12m Total Return: FATE (-71%) vs XBI (-14%)
5y Drawdown (Underwater) Chart
Top Performer in Biotechnology
Overall best picks of Peer Group - Selected by proven GARP Predictive Metrics, sorted by Growth Rating
| Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability | EPS CAGR |
|---|---|---|---|---|---|---|---|---|
| GILD NASDAQ Gilead Sciences |
-1.6% | 59% | 71.9% | 24.1 | 14.3 | 0.24 | 28.3% | -3.71% |
| UTHR NASDAQ United Therapeutics |
1.62% | -10.4% | 150% | 12 | 11 | 1.43 | 74.6% | 16.1% |
| AMGN NASDAQ Amgen |
-1.03% | -8.54% | 32.3% | 27.4 | 14.2 | 0.99 | 0.60% | 41% |
| NBIX NASDAQ Neurocrine Biosciences |
4.99% | -11% | 0.55% | 45.7 | 26.2 | 0.27 | 18.7% | -34.3% |
| BIM PA Biomerieux |
-0.99% | 26.5% | -5.28% | 32.7 | 25.8 | 1.55 | -38.5% | -25.1% |
| KMDA NASDAQ Kamada |
5.73% | 34.5% | -14.4% | 27.6 | 22.4 | 0.9 | 68.9% | 36.8% |
| PTCT NASDAQ PTC Therapeutics |
-7.94% | 44.1% | -14.3% | 7.54 | 6.09 | 0.81 | - | 68% |
| ERF PA Eurofins Scientific SE |
-1.76% | 27.6% | 14.6% | 28.9 | 15.4 | 0.64 | -62.1% | -19.3% |
Performance Comparison: FATE vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for FATE
| Total Return (including Dividends) | FATE | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -8.87% | 3.06% | 3.54% |
| 3 Months | 0.89% | 12.25% | 16.07% |
| 12 Months | -70.95% | -13.98% | 12.18% |
| 5 Years | -96.72% | -27.36% | 107.69% |
| Trend Score (consistency of price movement) | FATE | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -63.2% | 65.7% | 91.4% |
| 3 Months | 1.3% | 79.4% | 97.5% |
| 12 Months | -88.1% | -87.3% | 46.7% |
| 5 Years | -92.1% | -51.8% | 84% |
| Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
|---|---|---|---|
| 1 Month | %th18.00 | -11.57% | -11.98% |
| 3 Month | %th56.00 | -10.12% | -13.07% |
| 12 Month | %th20.50 | -66.23% | -74.10% |
| 5 Years | %th23.50 | -95.48% | -98.42% |
FAQs
Does Fate Therapeutics (FATE) outperform the market?
No,
over the last 12 months FATE made -70.95%, while its related Sector, the SPDR S&P Biotech (XBI) made -13.98%.
Over the last 3 months FATE made 0.89%, while XBI made 12.25%.
Performance Comparison FATE vs Indeces and Sectors
Above 0 means better perfomance compared to Symbol in this Timeframe
FATE vs. Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | 3.4% | -12.4% | -20% | -83% |
| US NASDAQ 100 | QQQ | 2.9% | -13.2% | -22.4% | -84% |
| German DAX 40 | DAX | 3.3% | -10.8% | -33% | -100% |
| Shanghai Shenzhen CSI 300 | CSI 300 | 2.8% | -13.8% | -24% | -90% |
| Hongkong Hang Seng | HSI | 2.8% | -11.3% | -42% | -105% |
| India NIFTY 50 | INDA | 5.1% | -9.5% | -21.4% | -68% |
| Brasil Bovespa | EWZ | 8% | -5.9% | -32.1% | -71% |
FATE vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | 4.4% | -10.7% | -24.1% | -95% |
| Consumer Discretionary | XLY | 3% | -11.5% | -11.3% | -87% |
| Consumer Staples | XLP | 5.2% | -8.1% | -20.7% | -78% |
| Energy | XLE | 5.5% | -8.6% | -9.8% | -69% |
| Financial | XLF | 4.7% | -11.4% | -19.5% | -93% |
| Health Care | XLV | 5.4% | -7% | -9.5% | -62% |
| Industrial | XLI | 3% | -13.5% | -25.9% | -93% |
| Materials | XLB | 6% | -10.5% | -17.8% | -72% |
| Real Estate | XLRE | 3.9% | -8.3% | -18.8% | -77% |
| Technology | XLK | 3% | -15.2% | -25.8% | -82% |
| Utilities | XLU | 2.6% | -10.8% | -22.7% | -92% |
| Aerospace & Defense | XAR | 0.5% | -18.1% | -40.5% | -120% |
| Biotech | XBI | 2.3% | -11.9% | -11.4% | -57% |
| Homebuilder | XHB | 5.1% | -14.4% | -6.6% | -64% |
| Retail | XRT | 4.6% | -11.7% | -15.8% | -76% |
FATE vs. Commodities
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Oil | USO | 5.9% | -4.63% | -3.62% | -65% |
| Natural Gas | UNG | -1.1% | -0.4% | 4.3% | -78% |
| Gold | GLD | 2.8% | -7.3% | -37.6% | -108% |
| Silver | SLV | 0.8% | -12.6% | -36.9% | -93% |
| Copper | CPER | 2.1% | -22.5% | -38.7% | -93% |
FATE vs. Bonds
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| iShares 20+ Years Bond | TLT | 4.9% | -8.7% | -14.5% | -66% |
| iShares High Yield Corp. Bond | HYG | 3.9% | -9.8% | -18% | -79% |